Cardiovascular-disorders
The Lancet
Diabetes & Endocrinology: Published: March, 2024Atherosclerotic cardiovascular
disease is a leading cause of death worldwide, and LDL cholesterol is a major
causal risk factor.Diabetes substantially increases
the risk of atherosclerotic cardiovascular disease.TAKE-HOME MESSAGEIn this
participant-level meta-analysis of 19 trials,...
Clinical studies have produced
conflicting evidence on the effects of the consumption of tomatoes on blood
pressure, and there are limited data from epidemiologic studies. This study
assesses whether tomato consumption (Solanum lycopersicum L.) is associated
with Systolic (SBP) and Diastolic Blood Pressure (DBP), and the risk of
hypertension i...
Effect of Initial Treatment with Quadpill vs Standard Dose Monotherapy in Patients with Hypertension
Circulation: AHA
Journals: Published
July, 2023Hypertension management remains suboptimal globally, with
treatment inertia being identified as one of the main barriers to achieving
blood pressure (BP) control. Simpler approaches to achieve target BP levels are
needed. TAKE-HOME MESSAGEThe QUARTET study examined the
effectiveness of a quadrupl...
American Journal of Obstetrics & Gynecology: Published: April,
2023Hypertensive disorders in pregnancy
(HDPs) are major causes of maternal and fetal morbidity and are associated with
future maternal risk of cardiovascular disease.Most existing data on hypertensive
disorders of pregnancy and short-term cardiovascular disease risks are limited
t...
AHA Journals (Circulation): Published on November, 2022Once patients have completed their
dual antiplatelet therapy, we need to stop one of the medications — which one
— ASA or clopidogrel? For many of us, we will keep the ASA and get rid of
the other agent like clopidogrel.This study in Korea included 5438
patients who had PCI with drug-elutin...
The New England Journal of Medicine: Published on December, 2022Hypertension increases the risk of complications and death
from cardiovascular disease. Thiazide diuretics are first-line
antihypertensive agents that lower blood pressure and prevent adverse
cardiovascular outcomes. Early studies suggested that chlorthalidone was superior to
hydro...
JAMA Cardiology: Published on April, 2022TAKE-HOME MESSAGEQuestion: Is
low-dose triple combination antihypertensive therapy associated with greater
time at target blood pressure compared with usual care?Findings: This
secondary analysis of an open-label randomized controlled clinical trial
evaluated whether low-dose triple combination antihyp...
The LANCET: Diabetes &
Endocrinology: Published on July, 2022Diabetes is a major cause of death,
cardiovascular complications, and health-care burden worldwide.People with type 2 diabetes who
have high blood pressure are at an increased risk of morbidity and death from
major cardiovascular events.However, there are inadequate
randomised contro...
The New England Journal of Medicine (NEJM): Published
on April, 2022Antihypertensive treatment during
pregnancy reduces the frequency of severe hypertension (blood pressure,
≥160/110 mm Hg) but has not been shown to improve maternal, fetal, or neonatal
outcomes and has been associated with an increased risk of
small-for-gestational-age birth w...
The 2021 WHO hypertension guideline
aims to provide the most current and relevant evidence based global public
health guidance on the initiation of treatment (with pharmacological agents)
for hypertension in adults. The recommendations target adult,
non-pregnant patients who were appropriately diagnosed with hypertension and counseled
about li...
AHA Journals: Hypertension: Published on May, 2022Diabetes is a strong risk factor
for end-stage renal disease (ESRD). Hypertension also plays a crucial role
in the development and progression of kidney failure. Blood pressure (BP)
rises with declining kidney function which in turn aggravates hypertension. Moreover, as chronic kidney disease
(C...
ACP Journals: Annals of Internal Medicine: Published on
November, 2022Current guidelines recommend using
direct oral anticoagulants (DOACs) over warfarin in patients with atrial
fibrillation (AF), but head-to-head trial data do not exist to guide the choice
of DOAC.The aim
of the study is to do a large-scale comparison between all DOACs
(apix...
